Logo-ipp
Submitted: 19 Sep 2021
Accepted: 27 Oct 2021
ePublished: 17 Apr 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Immunopathol Persa. 2023;9(2): 29293.
doi: 10.34172/ipp.2022.29293

Scopus ID: 85164616699
  Abstract View: 1030
  PDF Download: 484

Original

Cost-effectiveness analysis of infliximab versus CinnoRA in the treatment of moderate to severe ulcerative colitis in Iranian patients

Meysam Olfatifar 1 ORCID logo, Hamid Asadzadeh Aghdaei 2* ORCID logo, Ayda Hasanpour Dehkordi 3 ORCID logo, Shabnam Shahrokh 1, Mohamad Amin Pourhoseingholi 1 ORCID logo, Hedieh Balaii 2 ORCID logo, Mohsen Rajabnia 1 ORCID logo, Maria Ivanchuk 4 ORCID logo, Pavlo Ivanchuk 5 ORCID logo, Saeed Hashemi Nazari 6* ORCID logo, Siamak Sabour 7,8 ORCID logo, Pejman Rohani 9 ORCID logo, Gholamhossein Mehralian 10 ORCID logo, Soheila Khodakarim 11 ORCID logo, Behzad Hatami 1 ORCID logo, Habib Malekpour 2, Ghazal Sherkat 12 ORCID logo, Mohammad Reza Zali 1* ORCID logo, Sajjad Rahimi Pordanjani 13,14 ORCID logo

1 Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Centre, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Nickan Research Institute, Isfahan, Iran
4 Biological Physics and Medical Informatics Department, Higher State Educational Establishment of Ukraine, Bukovinian State Medical University, Chernivtsi, Ukraine
5 Internal Medicine, Physical Rehabilitation, Sports Medicine and Physical Training Department, Higher State Educational Establishment of Ukraine, Bukovinian State Medical University, Chernivtsi, Ukraine
6 Prevention of Cardiovascular Disease Research Centre, Department of Epidemiology, School of Public Health and Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran
7 Department of Clinical Epidemiology, School of Health and Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran
8 Safety Promotions and Injury, Prevention Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran
9 Pediatric gastroenterology, Hepatology and Nutrition Research Center, Research Institute for Children Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
10 School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
11 Department of Biostatistics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
12 Medical Student at Medicine Faculty of Mashhad Branch, Islamic Azad University, Mashhad, Iran
13 Social Determinants of Health Research Center, Semnan University of Medical Sciences, Semnan, Iran
14 Department of Epidemiology and Biostatistics, Semnan University of Medical Sciences, Semnan, Iran
*Corresponding Authors: Hamid Asadzadeh, Emails: Aghdaeihamidassadzadeh@gmail.com, , Email: Hamid.asadzadeh@sbmu.ac.ir; Saeed Hashemi Nazari, Emails:saeedh_1999@yahoo.com , , Email: Saeedh_1999@sbmu.ac.ir; Mohammad Reza Zali, Email: mrzaligi@gmail.com

Abstract

Introduction: As two biological agents, infliximab (IFX) and biosimilar adalimumab (CinnoRA®) are routinely used in the clinical management of ulcerative colitis (UC) in Iran.

Objectives: This study was done to evaluate the cost-effectiveness of IFX versus CinnoRA for the treatment of moderate-to-severe UC patients.

Patients and Methods: To accomplish this, we developed a hybrid decision-tree/microsimulation (MS) approach for modeling UC’s natural history. We populated our model with available data on probabilities, costs, utilities / disutilities, and emergent adverse effects. Costs were reported in Iranian Rial (IRR) and in April 2021 US dollars ($). One-way and multiple sensitivity analyses were used to determine the uncertainty of the model’s parameters.

Results: For five, 10, and lifetime horizon times, patients on IFX received slightly more quality-adjusted life-year (QALY) per year in remission and experienced about 3 to 5 times less surgery than CinnoRA patients. With willingness-to-pay (WTP) thresholds of 1800 ($7826.08), 820($3565.21), and 520 ($2260.86) million IRR for these horizon times, IFX was cost-effective with 100% certainty. Our findings were highly sensitive to the number of adverse effects.

Conclusion: Our results demonstrated that IFX is more effective and more costly than CinnoRA, and if we ignore the predicted surgeries, CinnoRA is nearly as effective as IFX. However, these findings should be cautiously interpreted without a robust clinical trial of CinnoRA in UC patients. Since the impact of CinnoRA may have been over/underestimated.


Citation: Olfatifar M, Asadzadeh Aghdaei H, Hasanpour Dehkordi A, Shahrokh S, Pourhoseingholi M A, Balaii H, Mohsen Rajabnia M, Ivanchuk M, Ivanchuk P, Hashemi Nazari S, Sabour S, Rohani P, Mehralian G, Khodakarim S, Hatami B, Malekpour H, Sherkat G, Zali M R, Rahimi Pordanjani S. Cost-effectiveness analysis of infliximab versus CinnoRA in the treatment of moderate to severe ulcerative colitis in Iranian patients. Immunopathol Persa. 2023;9(2):e29293. DOI:10.34172/ipp.2022.29293.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 1031

Your browser does not support the canvas element.


PDF Download: 484

Your browser does not support the canvas element.